SENTARA COMMUNITY PLAN (MEDICAID)

MEDICAL PRIOR AUTHORIZATION/STEP-EDIT REQUEST*

<u>Directions:</u> The prescribing physician must sign and clearly print name (preprinted stamps not valid) on this request. All other information may be filled in by office staff; <u>fax to 1-844-305-2331</u>. No additional phone calls will be necessary if all information (including phone and fax #s) on this form is correct. <u>If information provided is not complete, correct, or legible, authorization can be delayed</u>.

Botulinum Toxin Injections®, Type A

<u>Drug Requested</u>: Botox[®] (onabotulinumtoxinA) (J0585) (Medical) (Chronic Migraine Headache Prophylaxis)

MEMBER & PRESCRIBER INFOR	RMATION: Authorization may be delayed if incomplete.
Member Name:	
Member Sentara #:	Date of Birth:
Prescriber Name:	
Prescriber Signature:	
Office Contact Name:	
Phone Number:	
NPI #:	
DRUG INFORMATION: Authorization	n may be delayed if incomplete.
Drug Name/Form/Strength:	
	Length of Therapy:
Diagnosis:	ICD Code, if applicable:
Weight (if applicable):	Date weight obtained:
	e timeframe does not jeopardize the life or health of the member in function and would not subject the member to severe pain.

- Max quantity limits: 155 units once every 12 weeks
- Cosmetic indications are <u>EXCLUDED</u>

<u>NOTE</u>: In treating adult patients for one or more indications, the maximum cumulative dose should not exceed 400 units, in a 3-month interval. In pediatric patients, the total dose should not exceed the lower of 10 units/kg body weight or 340 units, in a 3-month interval.

(Continued on next page)

CLINICAL CRITERIA: Check below all that apply. <u>All criteria must be met for approval</u>. To support each line checked, all documentation, including lab results, diagnostics, and/or chart notes, must be provided or request may be denied.

Diagnosis: Chronic Migraine Headache Prophylaxis				
niti	al Authorization: 12 months			
	Has the member been approved for Botox previously through the Health Plan pharmacy department? □ Yes □ No			
	Member must be ≥ 18 years of age			
	Member experiences ≥ 15 headache days per month			
	Member experiences headaches which last ≥ 4 hours per day			
	Member must have failed a <u>2-month</u> trial of at least one medication from <u>TWO (2)</u> different migraine prophylactic classes supported by American Headache Society/American Academy of Neurology treatment guidelines 2012/2015/2021/2024, Level A and B evidence; ICSI 2013, high quality evidence (verified by pharmacy paid claims or submitted chart notes):			
	☐ Anticonvulsants (divalproex, valproate, topiramate)			
	☐ Beta blockers (atenolol, metoprolol, nadolol, propranolol, timolol)			
	☐ Antidepressants (amitriptyline, venlafaxine)			
	 □ Angiotensin II receptor blocker (candesartan) *requires prior authorization* □ Injectable CGRP inhibitors (Aimovig®, Emgality®, Ajovy®) or oral CGRP inhibitors indicated for migraine prevention (Qulipta™, Nurtec ODT™) * requires prior authorization* 			
	Member has been evaluated for medication overuse headache (MOH) (defined as headaches occurring greater than or equal to 15 days per month. It develops as a consequence of regular overuse of acute of symptomatic headache medication for more than 3 months)			
	Treatment will include a plan to taper off the offending medication if MOH is diagnosed			
uppo	uthorization: 12 months. Check below all that apply. All criteria must be met for approval. To ort each line checked, all documentation, including lab results, diagnostics, and/or chart notes, must be ded or request may be denied.			
	Member has experienced a positive response to therapy, demonstrated by a reduction in headache frequency			
	Use of acute migraine medications (e.g., NSAIDs, triptans) has decreased since the start of Botox®			
	Member continues to be monitored for medication overuse headache (MOH)			

(Continued on next page)

Medication being provided by (check box below that applies):				
□ Physician's office	OR	□ Specialty Pharmacy – Proprium Rx		
standard review would subject t	the member to ad	ntara Health Pre-Authorization Department if they believe a dverse health consequences. Sentara Health's definition of urgent rdize the life or health of the member or the member's ability to		
		does not meet step edit/preauthorization criteria.**		
* <u>Previous therapies will l</u>	<u>be verified thro</u>	ough pharmacy paid claims or submitted chart notes.*		